ACM
ZYNE

Aquatic Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Aquatic Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,900
Closed -$4K – 1672
2022
Q1 		$4K Buy
+1,900
New +$4.52K 0.01% 885

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Aquatic Capital Management's ZYNE Position: Q2 2022 in Review

Aquatic Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2022, closing a stake of 1,900 shares — an estimated $4K sold.

Aquatic Capital Management first reported a position in ZYNE in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 56 funds tracked by Wall St. Rank hold ZYNE as of Q2 2022.

  • Aquatic Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2022 after selling out during the quarter.
  • Aquatic Capital Management sold 1,900 Zynerba Pharmaceuticals, Inc shares in Q2 2022, an estimated $4K.
  • Aquatic Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2022 and held it in 1 quarter.
  • Aquatic Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $4K in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2022.

Based on Aquatic Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.